Counseling on Seroconversion Risk for Patients Starting Cabotegravir PrEP
Introduction to Cabotegravir PrEP Management
- The American Medical Association recommends that if seroconversion occurs while on cabotegravir PrEP, immediately obtain genotypic resistance testing including integrase mutations and switch to a protease inhibitor or NNRTI-based antiretroviral regimen—never continue an integrase inhibitor-based regimen due to high risk of multi-drug resistance 1, 2, 3
Ongoing HIV Testing Requirements
- Before each subsequent injection (every 8 weeks), perform both a rapid point-of-care HIV antibody test AND send a laboratory-based combination antigen/antibody test, as recommended by medical guidelines 1, 2, 3
Specific Treatment Protocol if Seroconversion Occurs
- Immediately transition to a protease inhibitor or NNRTI-based antiretroviral regimen (NOT an integrase inhibitor-based regimen) if seroconversion is detected, and obtain genotypic testing including specific integrase resistance testing, as per standard medical practice 1, 2, 3
Patient Education and Adherence
- Patients must return for HIV testing before every injection—missing this testing could result in undetected HIV infection and drug resistance, according to medical guidelines 1, 2, 3
- Never skip pre-injection HIV testing even if the patient seems low-risk or was recently tested, as advised by medical experts 1, 2, 3
- Never continue cabotegravir or switch to another integrase inhibitor if seroconversion is detected, as this will select for multi-drug resistant virus, as warned by medical guidelines 1, 2, 3
Window Period for Cabotegravir
Dosing Schedule
- The initial two injections of cabotegravir are given 4 weeks apart, followed by subsequent injections every 8 weeks, with each injection consisting of 600 mg administered intramuscularly in the gluteal region, as recommended by Praxis Medical Insights 4
- Subsequent injections of cabotegravir are administered every 8 weeks, as reported by JAMA 5
Critical Implementation Considerations
- Comprehensive HIV testing, including combination antigen/antibody test and HIV RNA test, should be performed before each injection of cabotegravir, as emphasized by Praxis Medical Insights 4, 6
- Cabotegravir can delay HIV seroconversion and mask early infection, highlighting the importance of thorough testing before each injection, according to Praxis Medical Insights 6
Common Pitfalls to Avoid
- Standard antibody tests alone may miss acute HIV infection, particularly given cabotegravir's long half-life and resistance risk, underscoring the need for HIV RNA testing, as noted by Praxis Medical Insights 4, 6